ANP Stock Overview
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia.
Antisense Therapeutics Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.086|
|52 Week High||AU$0.35|
|52 Week Low||AU$0.073|
|1 Month Change||-18.57%|
|3 Month Change||4.27%|
|1 Year Change||-56.15%|
|3 Year Change||-11.86%|
|5 Year Change||151.47%|
|Change since IPO||-96.44%|
Recent News & Updates
We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|ANP||AU Pharmaceuticals||AU Market|
Return vs Industry: ANP underperformed the Australian Pharmaceuticals industry which returned -23.6% over the past year.
Return vs Market: ANP underperformed the Australian Market which returned -10.8% over the past year.
|ANP Average Weekly Movement||14.7%|
|Pharmaceuticals Industry Average Movement||10.7%|
|Market Average Movement||9.4%|
|10% most volatile stocks in AU Market||16.5%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: ANP is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ANP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company’s product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial.
Antisense Therapeutics Limited Fundamentals Summary
|ANP fundamental statistics|
Is ANP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANP income statement (TTM)|
|Cost of Revenue||AU$65.68k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0087|
|Net Profit Margin||-326.89%|
How did ANP perform over the long term?See historical performance and comparison